Generex Biotechnology Corp (OTCPK:GNBT) announced early Tuesday that its Ii-Key/HER-2/neu immunotherapeutic vaccine showed anti-tumor activity. The study was a collaboration between Generex's immunotherapeutic division, Antigen Express, and the laboratory of Dr. Costas Baxevanis.
The study, "Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors", was published in the journal Cancer Immunology, Immunotherapy.
The results also show positive anti-tumor activity against human ovarian cancer cells in an animal model. These findings are a great complement to trials using Antigen Express's Ii-Key/HER-2/neu hybrid peptide AE37 in breast cancer patients.
On Septemberr 27 Torc Investments and Research initiated coverage of Generex with a buy recommendation and a price target of $3.00-$3.50. This was following a mid-September announcement that the company's Glucose RapidSpray will begin sales in October.
Company insiders and directors have shown great confidence in share value as they bought a large number of shares back in May.
GNBT 1-yr chart: